Abstract
Introduction. A pressing issue in contemporary medicine is the optimization of nonsteroidal anti-inflammatory drug (NSAID) use to enhance therapeutic efficacy while minimizing the risk of adverse effects. Increasing evidence indicates that these outcomes are influenced by population genetic and ethnic differences associated with variations in allele frequencies. The aim of the study was to identify the main approaches to optimizing the use of nonsteroidal anti-inflammatory drugs by integrating pharmacogenetic data and racial and ethnic characteristics of patients. Materials and methods. This study was based on an analysis of publications selected from the PubMed, Scopus, Web of Science, and Google Scholar scientific databases for the period from 2019 to 2025. The study used methods of comparative analysis and synthesis, systematization, and generalization. Results. Pharmacogenetics indicates that genetic variations affecting enzymes responsible for the metabolism of nonsteroidal anti-inflammatory drugs (NSAIDs) can influence drug concentration, duration of action, and the risk of adverse effects. The distribution of key pharmacogenetic variants across different ethnic populations has been characterized, providing a basis for the development of personalized approaches to NSAID therapy. The present study demonstrates that optimizing NSAID use requires the integration of pharmacogenetic data with racial and ethnic characteristics. Genetic studies have identified polymorphisms in genes such as CYP2C9, CYP2C8, ABCB1, SLCO1B1, PTGS1, and PTGS2, which contribute to interindividual variability in drug metabolism, bioavailability, and susceptibility to adverse reactions. The CYP2C92* allele is most prevalent in Middle Eastern and European populations and is rare in sub-Saharan African and East Asian populations. In contrast, the highest frequency of the CYP2C93* allele has been observed in Asian populations, followed by those in Southern Europe. These interethnic differences necessitate the adaptation of therapeutic algorithms and support the transition from standardized to personalized treatment strategies. The implementation of individual genotyping, expansion of pharmacogenetic testing panels, and the use of population-based data in the absence of individual testing may reduce the incidence of adverse effects and improve therapeutic efficacy. Conclusions. Ethnic variability in genetic markers significantly influences the efficacy and safety of NSAID therapy. The integration of pharmacogenetic data with ethnic variability facilitates the transition toward personalized medicine and enhances the safe and effective use of NSAIDs.

This publication has 15 references indexed in Scilit: